Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-05-27
2008-05-27
Pak, Michael (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
10618126
ABSTRACT:
This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides are shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptides of this invention are also stable in formulation and have long half-lives. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VPAC2-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.
REFERENCES:
patent: 6972319 (2005-12-01), Pan et al.
Dumas Michael L.
Froland Wayne A.
Kelner Drew N.
Pan Clark
Wang Wei
Bayer HealthCare AG
Edwards Angell Palmer & & Dodge LLP
Loren, Esq. Ralph A.
Pak Michael
LandOfFree
Pituitary adenylate cyclase activating peptide (PACAP)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pituitary adenylate cyclase activating peptide (PACAP)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pituitary adenylate cyclase activating peptide (PACAP)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3907110